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Abstract
Sphingolipids are found in all eukaryotic and some prokaryotic cells. Milk and dairy products 
are one of the most important sources of sphingolipids. This compounds participate in a variety of 
indispensable metabolic, neurological, and intracellular signaling processes. Sphingolipids and their 
derivatives are highly bioactive compounds with anti-cancer, bacteriostatic and cholesterol-lowering 
properties. Therefore, this review focuses on the potential health benefits of the milk and dairy 
sphingolipids.
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Introduction
Milk and dairy products, which provide one 
third of the total daily intake, are one of the most 
important sources of sphingolipids. Sphingolipids 
are not “ordinary fats”. They are better categorized 
as “functional ingredients” since they have not only 
structural, but also regulatory functions, and are 
effective already at low concentrations. 
The health benefits of milk and fermented 
products have been known since medieval times. 
Milk is an important food in the human diet, not 
only as the sole source of nutrition for infants but 
also as a source of energy in the form of fat, protein 
and carbohydrate for children and adults. Directly 
transferred from the mother to the newborn, all the 
constituents of milk are in their natural state and 
adapted to bring energy and bioactive molecules. 
Milk from animals is also transformed into various 
dairy products for infant and adult human consump-
tion. Aside from the nutritious value consisting of 
basic proteins, lipids and saccharides, milk contains 
also numerous biologically active substances, such 
as imunoglobulins, enzymes, antimicrobial peptides, 
oligosaccharides, hormones, cytokines and growth 
factors (Donovan, 2006; Pouliot and Gauthier, 
2006; Tunick and Van Hekken, 2014). 
Milk lipids 
Milk contains about 3 to 5 % (w/w) fat, but the 
absolute percentage of fat in milk varies according to 
multiple factors that include species, maternal diet 
and stage of lactation. Lipids contained in milk fat 
of mammals vary widely in content and composition 
(Jensen, 2002). Lipids are present in milk in the 
form of spherical entities of about 4 to 5 µm diam-
eter called milk fat globules, which are enveloped by 
a biological membrane known as the milk fat globule 
membrane (MFGM). This is highly complex biologi-
cal membrane that surrounds the fat globule, hereby 
stabilizing it in the continuous phase of the milk, and 
preventing it from enzymatic degradation by lipases 
(Danthine et al., 2000). Many detailed investi-
gations of the MFGM composition and structure 
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(Figure 1) as well as it’s technological, nutritional 
and health properties have been recently performed 
and reported in scientific reviews (Dewettinck et 
al., 2008; Gallier et al., 2012). Organization of the 
MFGM as a trilayer structure is now well accepted, 
with the inner layer composed of proteins and polar 
lipids from the endoplasmic reticulum and the outer 
bilayer of polar lipids originating from specialized 
secretory regions of the apical plasma membrane of 
the mammary epithelial cells (Heid and Keenan, 
2005). The lipids of the MFGM are primarily polar 
lipids, although neutral lipids can also occur. The la- 
tter are triglycerides, diglycerides, monoglycerides, 
cholesterol and its esters. The polar lipids of the 
MFGM consist of phospho- and sphingolipids. 
Nature and characteristics of phospholipids 
Phospholipids are amphiphilic molecules with 
a hydrophobic tail and hydrophilic head group. The 
phospholipids found in most cell membranes are ba-
sically glycerophospholipids, which consists of fatty 
acids esterified to a glycerol backbone, a phosphate 
group and a hydrophilic residue (e.g. choline, etha-
nolamine, serine, and inositol). Thus, the MFGM 
is composed of phosphatidylcholine, phosphatidy-
lethanolamine, phosphatidylinositol and phosphati-
dylserine. In addition to their structural roles, phos-
pholipids participate in a variety of indispensable 
metabolic, neurological and intracellular signaling 
processes (Guo et al., 2005).
The backbone of phospholipids can also be 
the long chain amino-alcohol sphingosine instead 
of glycerol. These phospholipids are classified as 
sphingophospholipids, the most representative being 
sphingomyelin (Figure 2), consisting of sphingosine 
esterified to one fatty acid and phosphocholine.
Beside sphingophospholipids, the MFGM is 
composed of sphingolipids, such as gangliosides 
(Dewettinck et al., 2008; Lopez, 2011; Gallier 
et al., 2014).
Figure 1. Structures of milk fat globule membrane 
Figure 2. Structure of sphingomyelin
Figure 3. Structures of sphingoid bases and ceramide
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Sphingolipids
Sphingolipids are ubiquitous lipids that were 
evolutionarily conserved among all eukaryotes. At 
the most basic level, they can be defined as any 
lipid molecule that contains the sphingoid backbone, 
derived from condensation of an amino acid (pre-
dominantly serine) and a fatty acid (predominantly 
palmitate) (Merrill, 2011). For many years, these 
molecules were considered structural components 
of biologic membranes; however studies over more 
than two decades have disclosed important biologic 
activities of many sphingolipids. 
Structure and classification
The core of an SPL is an organic aliphatic amino 
alcohol, termed a sphingoid base. There are above 
60 different sphingoid base backbones that vary in 
alkyl chain lenghts (Merrill, 2011), the degree of 
saturation and position of double bonds (Pruett 
et al., 2008) and the presence of a hydroxyl group 
(Hama, 2010). Mammalian organisms contain 
(Figure 3), mainly sphingosine (trans-4-sphingenine, 
d18:1D4), sphinganine (dihydrosphingosine, d18:0) 
and phytosphingosine (t18:0, 4-hydroxysphinganine) 
(Dickson, 2008). The presence or the absence of an 
acyl chain distinguishes ceramide from sphingosine 
(Figure 3), while phosphorylation of the 1-hydroxy 
group generates ceramide-1-phosphate or sphin-
gosine-1-phosphate. Other common sphingolipids 
contain different headgroups at this position. due to 
the differing acyl CoAs that can be used to produce 
it, ceramide is technically a class of molecules rath-
er than a single molecule and therefore may have 
different biological functions depending on the acyl 
chain it is composed of. 
The most structurally diverse sphingolipids are 
glycosphingolipids which are produced from cera-
mide precursors, why they may differ in their acyl 
chain composition, revealing an additional layer 
of variation.The head group of glycosphingolipids 
always consists of one or more sugar residues attached 
to the 1-hydroxyl group. Cerebrosides are simple 
glycosphingolipids which have a hexose linked to 
the 1-hydroxyl position through a β-glycosidic bond. 
Physiologically important representatives of the 
cerebrosides are glucosyl- and galactosyl-ceramide. 
One of the most differentiated series are gan-
gliosides, acidic glycosphingolipids with at least 
three sugars. One of them is sialic acid, also called 
N-acetylneuraminic acid (Neu5Ac). Due to the large 
head group, the number of different gangliosides is 
correspondingly large.
Sphingolipids can be synthesized de novo by a 
single biosynthetic pathway, with the end product 
being ceramide (Bartke and Hannun, 2009). 
Table 1. Sphingolipids content of different dairy products
aA conversion factor of 751 gmol-1 was used
bA conversion factor of 1 g mL-1 was used
Sample Sphingolipids (mg 100 g-1 product) Reference
Butter 71,0 Rombaut et al. (2006)
Buttermilk 19,0 Rombaut et al. (2005)
Cream 49,0 Rombaut et al. (2006)
Skimmed milk 6,0 Rombaut et al. (2006)
Swiss cheese 8,4 a Ahn and Schroeder (2002b)
Whey (Cheddar) 5,0 Rombaut et al. (2005)
Whey (Emmenthal) 3,0 b Theodet and Gandemer (1994)
Whey (Emmenthal) 4,0 b Baumy et al. (1990)
Whole milk 4,9 b Christie et al. (1987)
Yoghurt 2,8 a Ahn and Schroeder (2002b)
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Within the cells, sphingolipids are mainly found 
in the plasma membrane, the Golgi apparatus and in 
the lysosomes. Thus, sphingolipids can be expected 
in minor amounts in all food products. 
Sphingolipids in food
Sphingolipids are present in nearly all foods 
and their amounts vary considerably. Milk and dairy 
products, which provide a third of the total intake, 
are one of the most important sources of sphingolip-
ids (Table 1). Dairy products followed by meat and 
fish, eggs, and vegetables (Vesper et al., 1999). 
Based on a yearly per capita food consumption of 
873 kg, sphingolipids constitute from 0.01 to 0.02 % 
of the diet (by weight). The quantities range from a 
few µg/kg in fruit and some vegetables up to 1 g/kg in 
dairy products, meat, eggs and soybeans (Vesper et 
al., 1999). As in many foods, sphingomyelin also ac-
counts for the major portion of sphingolipids in dairy 
products. Sphingomyelin occupies a special place 
as a sphingophospholipid. Milk and dairy products 
contain around 0.3-1 % of total fat as phospholipids. 
Approximately 60 % of the total phospholipids in 
milk are found in the milk fat globule membrane. 
Some milk by products such as buttermilk and es-
pecially its MFGM fraction contain up to 40 % (in 
weight) of phospholipids, of which 30 % is phos-
phatidylethanolamine, 7 % is phosphatidylinositol, 
5 % is phosphatidylserine, 31 % is phosphatidylcho-
line, and 20 % is sphingomyelin (Fong et al., 2007; 
Rodriguez-Alcala and Fontecha, 2010). The 
season and stage of lactation affect the sphingolipid 
content in the milk (Parodi, 1997). The content of 
membrane lipids, and consequently also sphingolip-
ids, decreases along with lactation progress due to 
fewer presence of larger milk fat globules with thinn- 
er globule membrane (Bitman and Wood, 1990). 
Structures of sphingolipids vary considerably 
with the type of food. In milk is mostly found sphin-
gomyelin, but also a considerable amount of lactosyl-
ceramide, glucosylceramide, gangliosides (Jensen, 
2002) and less amounts of sphingoid bases (Ribar et 
al., 2006; Ribar et al., 2007). Even more structural 
diversity is achieved by variations in the sphingoid 
base backbone and amide-bound fatty acids. These 
possible variations make sphingolipids structurally 
the most diverse class of membrane lipids.
Sphingolipids from food are most probably 
not essential for normal growth and development 
since most sphingolipids are synthesised de novo 
(Vesper et al., 1999). Nonethless both, complex 
sphingolipids and their digestion products (cera-
mides and sphingosines) as well are highly bioactive 
compounds with profaund effects on cell regulation. 
Sphingolipids from food cross the intestinal mem-
brane and are biologically active, particularly in in-
hibiting colon carcinomas (Dillehy et al., 1994). 
Digestion and degradation of sphingolipids
Before humans can actually utilise sphingolip-
ids, they must be released from the food matrix by 
digestive enzymes. Dietary phospholipids and sphin-
golipids are not acted upon by lingual and gastric 
lipases, but the pancreatic one (occurring in in the 
intestinal lumen) does cleave fatty acids from their 
sn-2-position. Sphingomyelin leaves the stomach in 
a predominantly intact state and is first hydrolysed 
in the subsequent sections of the small and large in-
testine (Nyberg et al., 1997). The alkaline sphingo-
myelinase catalyses hydrolysis of sphingomyelin into 
ceramide and phosphocholine (Duan et al., 1995). 
Enzymatic activity of sphingomyelinase is low in the 
duodenum and reaches the highest level in the mid-
dle and lower parts of the small intestine (Nyberg 
et al., 1997; Duan et al., 1995). Subsequently, cera-
mides can be further hydrolyzed to sphingosine and 
fatty acid by ceramidase, which cleaves the amide 
bond. All of them then enter the enterocyte. 
In many foodstuffs, glycosphingolipids occur 
in smaller quantities than sphingomyelin and 
are structurally more diverse. Degradation of 
glycosphingolipids occurs in the acidic compart-
ments (lysosomes and endosomes) of the cell. 
Different hydrolases (depending on the sugar resi-
due of the glycosphingolipid) cleave the sugar resi-
dues from the non-reducing end. The resulting mono 
saccharides, sialic acid, fatty acids and ceramides 
leave the lysosomes and are further degraded, 
absorbed or reintegrated into the sphingolipid 
cycle (Sandhoff and Kolter, 2003). Ceramide 
and sphingosine absorbed by the cells are either 
further broken down and become bioactive, or are 
again converted to complex sphingolipids (Merrill 
et al., 1995). 
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Sphingolipids activity 
For many years, sphingolipids were considered 
as structural components of biologic membranes. 
However studies performed over more than two 
decades disclosed important biologic activities of 
many sphingolipids. Sphingolipids are abundant in 
the apical membrane and in the absorptive epithe-
lium in the gut (Danielsen and Hansen, 2006), 
while their digestion products (ceramides and sphin-
gosine) are considered as the most bioactive com-
pounds, having important effects on the cell regu-
lation. Sphingolipids such as sphingosine, ceramide, 
sphingosine-1-phosphate have been implicated as 
modulators of physiologic and pathophysiologic pro-
cesses such as cell growth, cell death, autophagy, 
angiogenesis, cell adhesion, differentiation, migra-
tion, senescence, intracellular trafficking, stress 
(Nikolova-Karakashian and Rozenova, 2010; 
Stancevic and Kolesnick, 2010) and inflamma-
tory responses (El Alwani et al., 2006). Ceramide 
and sphingosine-1-phosphate (S1P) often exert op-
posing functions in the cell; as ceramide has been 
shown to mediate cell cycle arrest and cell death in 
response to cell stress (Hannun and Obeid, 2011), 
sphingosine-1-phosphate has been shown to pro-
mote cell survival and proliferation (Maceyka et 
al., 2009). Alterations in bioactive sphingolipids and 
their metabolism have been linked to several human 
diseases including cancer (Zeidan and Hannun, 
2007; Furuya et al., 2011). 
Health benefits of dietary sphingolipids
Effects of sphingolipids on cancer
Alongside classical pharmaceutical interven-
tions to reduce the progression or the risk of several 
diseases, there is an increasing interest in nutraceu-
ticals, or functional foods, as part of encouraging 
lifestyle intervention. There is no known nutritional 
requirement for sphingolipids in the diet. However, 
it has been reported that dietary supplementation 
with sphingolipids has diverse physiological ben-
efits. Many in vitro and in vivo studies focused on 
the health effects of sphingolipids. Most research is 
centered on some cancers and neurological patholo-
gies. Ceramides and sphingosine, the digestion prod-
ucts of sphingolipids, affect cell growth, differentia-
tion and apoptosis, suggesting that their release may 
affect the behavior of normal or transformed cells, 
especially in the intestine (Duan and Nilsson, 
2009). Dietary sphingolipids may be the key link 
connecting diet, inflammation and cancer (Canela 
et al., 2016). Sphingolipids may enhance or inhibit 
carcinogenesis, depending on their source and abil-
ity to be metabolized to sphingosine-1-phosphate 
(Degagne et al., 2014). The majority of “cancer 
and sphingolipids” studies concern colon cancer. The 
effect of dietary sphingolipids in colon cancer was 
actively studied both in vitro and in vivo. Evidence 
of the importance of dietary sphingolipids in fight-
ing colorectal cancer was first described by Dudeja 
et al. (1986), who found differences in both sphin-
golipid composition and sphingolipid enzyme ac-
tivities between tumor and normal tissue. Certain 
sphingolipids are also active against other cancer 
types, such as enigmol, a sphingoid base analog 
(Symolon et al., 2011). Sphingoid bases are cyto-
toxic for many cancer cell lines and are thought to 
contribute to suppression of intestinal tumorigenesis 
in vivo by ingested sphingolipids. Enigmol represents 
a novel category of sphingoid bases analogue that is 
orally bioavailable and has the potential to be effec-
tive against multiple types of cancer. 
Sphingomyelin is one of the best-studied com-
pounds in chemoprevention, ought to its roles as 
messenger in the development, growth, differentia-
tion, and apoptosis of human cells. Therefore, seve- 
ral studies suggested its use in adjunct colon can-
cer treatment (Kuchta et al., 2012). In synthesis, 
sphingomyelin isolated from milk fat reduced the 
number of cryptic foci and prevented 1, 2-dimethyl-
hydrazine-induced colon cancer in ICR rats and CF1 
mice (Zhang et al, 2008; Dillehay et al., 1994). In 
colon cancer cells and mice models, sphingomyelin 
and glycosphingolipids from milk reduce the num-
ber of aberrant colonic crypt foci (Dillehay et al., 
1994; Schmelz et al., 1996; Schmelz et al., 2000; 
Kurek et al., 2013). Milk-derived sphingomyelin 
also transformed adenocarcinomas to more benign 
adenomas (Schmelz et al., 1996) and exhibited 
chemopreventive and chemotherapic effects in CF1 
mice (Lemonnier et al., 2003). Due to its content 
of long chain saturated fatty acids, sphingomyelin 
highly contributes to form, together with cholester-
ol, the rigid membrane domains, called “lipid rafts”. 
Consequently, the regulation of the composition and 
density of lipid rafts could potentially alter cancer 
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cell viability and metastatic behavior (Küllenberg 
et al., 2012). Non-pharmacological amounts of 
sphingomyelin in the diet showed chemopreventive 
and chemotherapeutic effects on chemically induced 
colon cancer in mice (Lemonnier et al., 2003). The 
chemopreventive effects of sphingomyelin appear to 
be due to its principal metabolites, i.e. sphingosine, 
sphingosine-phosphate, and ceramide, all of which 
induce apoptosis (Patwardhan et al., 2016).
Sphingoid bases and ceramide have been shown 
to induce apoptosis in colon cancer cells and sugges- 
ted as potential mediators of the protective role of 
more complex dietary sphingolipids in colorectal 
cancer development (Ahn and Schroeder, 2002a). 
Ceramide production and its biological function are 
highly dependent on the length of the covalently 
linked fatty acid. The interplay between ceramides 
of various chain lengths seems to be crucial for can-
cer progression. Specific sphingolipids (and bioac-
tive sphingolipid metabolites) together with changes 
in the expression and/or function of sphingolipid-
metabolizing enzymes, could impact therapeutic 
response.
Altered sphingolipid composition was shown in 
colon cancer cells (Van Blitterswijk et al, 1984). 
There is increasing evidence that alteration in sphin-
golipid metabolism can modulate susceptibility to in-
testinal tumorigenesis. Indeed, dietary sphingolipids 
have both, chemopreventive and chemotherapeutic 
effects in colon cancer animal models. In addition, 
modulation of the enzymes implicated in sphingolip-
id metabolism seem to change the susceptibility to 
colon cancer formation as shown in the SK1-/-  model 
following AOM/DSS treatment (Kawamori et al., 
2009). 
Role of sphingolipids in binding and inactivation of 
toxins and bacteria
It is well known that appropriate consumption 
of gangliosides through milk and other dairy products 
may protect from infections by binding and inactivat-
ing certain bacteria, viruses and their toxins (Rueda, 
2007). Gangliosides which are profusely present on 
the surface of the apical membrane of enterocytes 
function as binding sites for bacteria and their toxins 
to prevent translocation of pathogens from the gut 
to the internal environment. Bacteria, viruses and 
toxins are inactivated after binding with glycosphin-
golipids, and by exogenous sphingolipids (provided in 
diet) protect passage of the microorganisms through 
the intestinal mucosa. For example, bacterial toxins 
of Shigella and Escherichia or rotaviruses are bound 
and inactivated (Lafont et al., 2002; Lanne et 
al., 1995; Rolsma et al., 1998). Oral administra-
tion of gangliosides has resulted in the regresion of 
H. pylori infection (Miller-Podraza et al., 2004; 
Wada et al., 2010). Sprong et al. (2001) reported 
that milk fat sphingomyelin and lyso-sphingolipids 
are potent anti-bacterial agents that increase resist-
ance toward intestinal pathogens (E. coli, Salmonella 
enteritidis, Campylobacter jejuni, Listeria monocy-
togenes) mostly due to the medium-chain (C10:0 
and C12:0) fatty acids of the lyso-derivatives. Haug 
et al. (2007) observed that gangliosides contained 
in MFGM modify the gastrointestinal receptor for 
microbial toxins, thereby partially preventing some 
digestive disorders. Proper gangliosides supplemen-
tation, for example, by consumption of milk, eggs, 
and other dairy products may protect from infec-
tions through binding and inactivation of bacterial 
toxins (Birecki et al., 2006; Rueda, 2007). There-
fore, it can be concluded that dietary sphingolipids, 
particularly milk and egg gangliosides, may protect 
gut against infections through binding and inactiva-
tion of microbes and their toxins. 
Relation between dairy sphingolipids intake and 
cognitive function
Few observational findings suggest that dairy 
food intake may be positively related to cognitive 
functions (Eskelinen et al., 2008; Vercambre et 
al., 2009; Park and Fulgoni, 2013). Sphingomy-
elin and sphingolipid metabolites are fundamental 
components in the central nervous system of my-
elin sheat that surrounds the axons of some neurons. 
A research on developing rats demonstrated that 
sphingolipids, especially sphingomyelin from milk, 
can contribute to the myelination of the central 
nervous system (Oshida et al., 2003). Tanaka et al. 
(2012) carried out a study on premature infants and 
showed that the administration of sphingomyelin-
fortified milk to the basis was positively associated 
with the neurobehavioral development. Recently, 
gangliosides have been associated with-enhancing 
spatial learning and affecting brain growth and com-
position in neonatal piglets (Liu et al., 2014). Stud-
ies focusing on dairy products-derived phospholipids 
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showed that consumption of one glass of milk per 
day does improve cognitive function and memory 
in adults (Crichton et al., 2012). Recently, Park 
and Fulgoni (2013) observed better global cogni-
tive function in adults and aged individuals who 
consumed milk goods as compared with those who 
abstained from such products.
Sphingolipids are associated with age-related 
diseases and the development of Alzheimer’s disease 
(Parodi, 2001), as sphingolipid signalling may play a 
role in the progressive loss of cell function during the 
aging process. There are studies supporting the hy-
pothesis that dietary phospholipids could contribute 
to the therapeutic approach to Alzheimer’s disease, 
even if this is still a controversial issue. 
Effects of sphingolipids on lipid profile, cholesterol 
and cardiovascular risk
Lipids, although essential for humans, were his-
torically thought to elevate blood cholesterol and 
were therefore considered as dangerous to health. 
That attitude has been changing in recent years. 
Sphingolipids are involved in the intestinal uptake of 
cholesterol. Dietary sphingolipids supplementation 
could limit cholesterol-related diseases by inhibiting 
their absorption in intestinal mucosal cells (Kurek 
et al., 2013). Sphingomyelin was found to dose-de-
pendently lower the intestinal absorption of choles-
terol and fats in rats (Eckhardt et al., 2002; Noh 
and Koo, 2003). Sphingomyelin affects different 
aspects of cholesterol transport and metabolism sug-
gesting that it may influence atherosclerosis (Vesper 
et al., 1999). Noh and Koo (2004) observed that 
milk sphingomyelin is more potent inhibitor of the 
intestinal absorption of cholesterol than egg sphin-
gomyelin and this behavior can be explained by the 
higher degree of saturation and longer chain length of 
the fatty acyl groups. Duivenvoorden et al. (2006) 
reported that dietary sphingolipids play an impor-
tant role in lowering plasma cholesterol and triacyl-
glycerol and protecting the liver from fat- and cho-
lesterol-induced steatosis. In addition, through the 
promotion of adiponectin signaling, dietary sphin-
golipids inhibit fatty liver, hipercholesterolemia, and 
insulin resistance (Yunoki et al., 2010; Bamba et 
al., 2012). It may be concluded that dietary sphin-
golipids hold great potential to treat multiple aspects 
of the metabolic syndrome, such as dyslipidemia, in-
sulin resistance and cardiovascular diseases. 
Effects of sphingolipids on the maintenance of skin 
homeostasis
Some studies indicate that the ingestion of 
sphingolipids, especially DHCer (dihydroceramide), 
confers beneficial effects for the restoration of per-
meability barrier dysfunction caused by ultraviolet 
(UV) B irradiation (Fukami et al., 2014). Russell 
et al. (2010) suggested that milk phospholipids, and 
in particular sphingomyelin, act upon skin cells pro-
tecting them against the effect of ultraviolet radiati-
on. Studies on some cell types indicated that sphin-
golipids may have a protective activity even against 
damage from g-irradiation and chemical agents 
(Vesper et al., 1999). Some studies have shown 
that GlcCer metabolism is essential to the mainte-
nance of skin homeostasis (Takagi et al., 2005). 
Conclusions
The public should be taught about the benefits 
of milk fat and of milk in general. Despite advertis-
ing and educational efforts, many consumers are still 
not fully aware that dairy foods are a good source of 
high quality ingredients. These efforts will have to 
be supported by further research on the mechanisms 
whereby milk components benefit humans. Although 
sphingolipids are probably not essential dietary com-
ponents, they can make a contribution to human 
health (Figure 4). Unfortunately nutritional science 
is at the time insufficiently familiar with their use in 
practice, effect on the plasma sphingolipids level and 
the effective quantity of the sphingolipids ingested. 
As scientists continue to investigate food as it relates 
to health, people will realize the importance of dairy 
products in the diet.
Figure 4. Health benefits of dietary sphingolipids
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Potencijalne zdravstvene dobrobiti  
sfingolipida mlijeka i mliječnih proizvoda
Sažetak
Sfingolipidi su prisutni u svim eukariotskim i 
nekim prokariotskim stanicama. Mlijeko i mliječni 
proizvodi su jedan od najvažnijih izvora sfingolipi-
da. Sfingolipidi sudjeluju u raznim prijeko potreb-
nim metaboličkim, neurološkim i unutarstaničnim 
signalnim procesima. Oni i njihovi derivati su vrlo 
bioaktivni spojevi s anti-tumorskim i bakteriostat-
skim svojstvima, a djeluju i na snižavanje kolesterola. 
Stoga je ovaj pregled usredotočen na potencijalne 
zdravstvene dobrobiti sfingolipida mlijeka i mliječnih 
proizvoda.
Ključne riječi: sfingolipidi, sphinzinske baze,  
gangliozidi, mlijeko, mliječni 
proizvodi
Explanation of abbreviation:
MFGM = milk fat globule membrane
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